Literature DB >> 17979945

B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle.

Fiona Bennett1, Andy Rawstron, Marieth Plummer, Ruth de Tute, Paul Moreton, Andrew Jack, Peter Hillmen.   

Abstract

The proliferating component in chronic lymphocytic leukaemia (CLL) is usually small (<1%) and restricted to a specific micro-environmental niche. To characterize the proliferating component, CLL cells from bone marrow or lymph nodes of 23 patients were assessed for expression of up to 66 surface antigens in combination with nuclear Ki-67/MCM6. Ki-67 expression was associated with step-wise increases in CD23/CD95/CD86/CD39/CD27 and decreases in CD24/CD69/CXCR4/CXCR5. Ki-67+ cells showed increased CD38 expression, but with considerable inter-patient variability: in some cases Ki-67 expression was only detectable in CD38- CLL cells. The results suggest continuous re-entry into the cell cycle as no distinct stem cell pool was detectable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979945     DOI: 10.1111/j.1365-2141.2007.06790.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

Review 1.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

2.  The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.

Authors:  Clive S Zent; Betsy R LaPlant; Patrick B Johnston; Timothy G Call; Thomas M Habermann; Ivana N Micallef; Thomas E Witzig
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

Review 3.  The pathogenesis of chronic lymphocytic leukemia.

Authors:  Suping Zhang; Thomas J Kipps
Journal:  Annu Rev Pathol       Date:  2013-08-26       Impact factor: 23.472

Review 4.  Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

Authors:  Jan A Burger; Emili Montserrat
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

Review 5.  PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Authors:  Klaus Okkenhaug; Jan A Burger
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

6.  Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Authors:  Thomas M Herndon; Shih-Shih Chen; Nakhle S Saba; Janet Valdez; Claire Emson; Michelle Gatmaitan; Xin Tian; Thomas E Hughes; Clare Sun; Diane C Arthur; Maryalice Stetler-Stevenson; Constance M Yuan; Carsten U Niemann; Gerald E Marti; Georg Aue; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Nicholas Chiorazzi; Adrian Wiestner
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

Review 7.  Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.

Authors:  Tiziana Vaisitti; Francesca Arruga; Giulia Guerra; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

8.  AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Authors:  Michael Huemer; Stefan Rebhandl; Nadja Zaborsky; Franz J Gassner; Stefan Hainzl; Lukas Weiss; Daniel Hebenstreit; Richard Greil; Roland Geisberger
Journal:  Eur J Immunol       Date:  2014-10-18       Impact factor: 5.532

Review 9.  Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

Authors:  Tiziana Vaisitti; Francesca Arruga; Silvia Deaglio
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

Review 10.  The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.

Authors:  Gabriele Brachtl; Josefina Piñón Hofbauer; Richard Greil; Tanja Nicole Hartmann
Journal:  Ann Hematol       Date:  2013-11-28       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.